Abstract
Eight new bisbenzimidazolium halides were prepared from alkyl halides and 4,4′-bis[(benzimidazol-1-yl)methyl]-1,1′-biphenyl.The structures of the benzimidazole salts were characterized using elemental analysis techniques as well as 1H, 13C NMR, and FT-IR spectroscopic methods. The inhibitory effects of the benzimidazole derivatives were measured against human carbonic anhydrase I (hCA I), human carbonic anhydrase II (hCA II), and acetylcholinesterase (AChE) enzymes. All benzimidazolium halides exhibited significant enzyme inhibitory properties. They showed highly potent inhibitory effect on AChE and hCAs (Ki values are in the range of 15.7 ± 0.8 to 49.7 ± 10.1 nM, 14.6 ± 1.5 to 70.7 ± 2.7 nM, and 17.4 ± 2.8 to 38 ± 10 nM for AChE, hCA I, and hCA II, respectively). The binding orientation of the synthesized bisbenzimidazolium halides was evaluated by molecular docking studies, reflecting the importance of the p-methylbenzyl, m-methylbenzyl, p-nitrophenethyl, and 3-(1,3-dioxoisoindolin-2-yl)methyl) groups in protein–ligand interaction. The docking results support the Ki values of the respective compounds in this study. The structure–activity relationships against the various targets are clearly shown in three dimensions at the atomic level by their interactions with the mentioned enzymes.
Graphical abstract
Similar content being viewed by others
Data availability
Data regarding the article can be accessed from the Supplementary information file at https://doi.org/10.1007/s00706-024-03204-5.
References
Brishty SR, Hossain MdJ, Khandaker MU, Faruque MRI, Osman H, Abdur Rahman SM (2021) Front Pharm 12:762807
Barot KP, Nikolova S, Ivanov I, Ghate MD (2013) Mini Rev Med Chem 13:1421
Küçükbay H, Yılmaz Ü, Şireci N, Güvenç AN (2011) Turk J Chem 35:561
Patil PO, Bari SB (2014) Arab J Chem 7:857
Atmaca H, İlhan S, Batır MB, Pulat ÇÇ, Güner A, Bektaş H (2020) Chem Biol Interact 327:109163
Bansal Y, Silakari O (2012) Bioorg Med Chem 20:6208
Tonelli M, Simone M, Tasso B, Novelli F, Boido V, Sparatore F, Paglietti G, Pricl S, Giliberti G, Blois S, Ibba C (2010) Bioorg Med Chem 18:2937
Menteşe E, Yılmaz F, Emirik M, Ülker S, Kahveci B (2018) Bioorg Chem 76:478
Kus C, Ayhan-Kilcigil G, Eke BC (2004) Arch Pharm Res 27:156
Abdel-Motaal M, Almohawes K, Tantawy MA (2020) Bioorg Chem 101:103972
Çağlayan C, Taslimi P, Demir Y, Küçükler S, Kandemir FM, Gulcin I (2019) J Biochem Mol Toxicol 33:e22381
Kalaycı M, Türkeş C, Arslan M, Demir Y, Beydemir Ş (2021) Arch Pharm 354:e2000282
Caglayan C, Taslimi P, Türk C, Gulcin İ, Kandemir FM, Demir Y, Beydemir Ş (2020) Environ Sci Pollut Res 27:10607
Sever B, Türkeş C, Altıntop MD, Demir Y, Beydemir Ş (2020) Int J Biol Macromol 163:1970
Askin S, Tahtaci H, Türkeş C, Demir Y, Ece A, Çiftçi GA, Beydemir Ş (2021) Bioorg Chem 113:105009
Hou Z, Li C, Liu Y, Zhang M, Wang Y, Fan Z, Guo C, Lin B, Liu Y (2020) J Enzyme Inhib Med Chem 35:383
Hoff E, Zou D, Schiza S, Demir Y, Grote L, Bouloukaki I, Hedner J (2020) J Sleep Res 29:e12956
Yamali C, Gul HI, Cakir T, Demir Y, Gulcin I (2020) Lett Drug Des Discov 17:1283
Cakmak O, Ökten S, Alımlı D, Ersanlı CC, Taslimi P, Koçyiğit ÜM (2020) J Mol Struct 1220:128666
Aydin BO, Anil D, Demir Y (2021) Arch Pharm 354:2000330
Tugrak M, Gul HI, Demir Y, Gulcin I (2021) Arch Pharm 354:2000230
Sever B, Türkeş C, Altıntop MD, Demir Y, Akalın Çiftçi G, Beydemir Ş (2021) Arch Pharm 354:2100294
Osmaniye D, Türkeş C, Demir Y, Özkay Y, Beydemir Ş, Kaplancıklı ZA (2022) Arch Pharm 355:e2200132
Kaya Y, Erçağ A, Zorlu Y, Demir Y, Gülçin İ (2022) J Biol Inorg Chem 27:271
Innocenti A, Ozturk Sarikaya SB, Gulcin I, Supuran CT (2010) Bioorg Med Chem 18:2159
Türkan F, Huyut Z, Demir Y, Ertaş F, Beydemir Ş (2019) Arch Physiol Biochem 125:235
Bilginer S, Anıl B, Koca M, Demir Y, Gülçin İ (2021) Turk J Chem 45:805
Mahmudov I, Demir Y, Sert Y, Abdullayev Y, Sujayev A, Alwasel SH, Gulcin I (2022) Arab J Chem 15:103645
Maharramov A, Kurbanova M, Taslimi P, Demir Y, Safarova A, Huseyinov E, Gulcin İ (2021) Org Commun 14:144
Tugrak M, Gul HI, Demir Y, Levent S, Gulcin I (2021) Arch Pharm 354:2000375
Manach C, Scalbert A, Morand C, Jimenez L (2004) Am J Clin Nutrit 79:727
Ellis J (2005) Am Osteopth Assoc 105:145
Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondžić AM, Vasić VM (2013) Curr Neuropharmacol 11:315
Akıncıoğlu A, Akıncıoğlu H, Gülçin İ, Durdagi S, Supuran CT, Göksu S (2015) Bioorg Med Chem 23:3592
Akıncıoğlu A, Topal M, Gülçin İ, Göksu S (2014) Arch Pharm 347:68
Wang L, Moraleda I, Iriepa I, Romera A, Lopez-Munoz F, Chioua M, Inokuchi T, Bartolini M, Marco-Contelles J (2017) Medchemcomm 8:1307
Gul Hİ, Yazici Z, Tanc M, Supuran CT (2016) J Enzyme Inhib Med Chem 31:1540
Kazancı A, Gök Y, Kaya R, Aktaş A, Taslimi P, Gülçin İ (2021) Polyhedron 193:114866
Saadiq M, Uddin G, Latif A, Ali M, Akbar N, Ammara AS, Ahmad M, Zahoor M, Khan A (2022) ACS Omega 7:705
Yılmaz Ü, Şireci N, Deniz S, Küçükbay H (2010) Appl Organomet Chem 24:414
Zengin R, Gök Y, Demir Y, Şen B, Taskin-Tok T, Aktaş A, Demirci Ö, Gülçin İ, Aygün M (2023) J Fluorine Chem 267:110094
Hsiao S-H, Teng C-Y, Kung Y-R (2015) RSC Adv 5:93591
Smith BC (2020) Spectroscopy 35:26
Ökten S, Aydın A, Koçyiğit ÜM, Çakmak O, Erkan S, Andac CA, Taslimi P, Gülçin İ (2020) Arch Pharm 3553:e2000086
Ellman GL, Courtney KD, Andres V Jr (1961) Biochem Pharm 7:88
Erdemir F, Celepci DB, Aktaş A, Gök Y, Kaya R, Taslimi P, Demir Y, Gulçin İ (2019) Bioorg Chem 91:103134
Erdoğan M, Polat Köse L, Eşsiz S, Gülçin İ (2021) Arch Pharm 354:e2100113
Hashmi S, Khan S, Shafiq Z, Taslimi P, Ishaq M, Sadeghian N, Karaman HS, Akhtar N, Islam M, Asari A, Mohamad H, Gulçin İ (2021) Bioorg Chem 107:104554
Burmaoglu S, Yilmaz AO, Polat MF, Kaya R, Gulcin İ, Algul O (2021) Arch Physiol Biochem 127:15
Verpoorte JA, Mehta S, Edsall JT (1967) J Biol Chem 242:4221
Efeoglu C, Selcuk O, Demir B, Sahin E, Sari H, Türkeş C, Demir Y, Nural Y, Beydemir Ş (2024) J Mol Struct 1301:137365
Bal S, Demirci Ö, Şen B, Taslimi P, Aktaş A, Gök Y, Aygün M, Gülçin İ (2021) Arch Pharm 354:e2000422
Demir Y, Duran HE, Durmaz L, Taslimi P, Beydemir Ş, Gulçin İ (2020) Appl Biochem Biotech 190:437
Demir Y, Taslimi P, Koçyiğit ÜM, Akkuş M, Özaslan MS, Duran HE, Budak Y, Tüzün B, Gürdere MB, Ceylan M, Taysi S, Gülçin İ, Beydemir Ş (2020) Arch Pharm 353:e2000118
Pedrood K, Sherafati M, Mohammadi-Khanaposhtani M, Asgari MS, Hosseini S, Rastegar H, Larijani B, Mahdavi M, Taslimi P, Erden Y, Günay S, Gulçin İ (2021) Int J Biol Macromol 170:1
Türkeş C, Demir Y, Beydemir Ş (2021) J Biomol Struct Dyn 39:1672
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JA Jr, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Keith T, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Iyengar SS, Tomasi J, Cossi M, Rega N, Millam JM, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas O, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ (2009) Gaussian 09, Revision E.01. Gaussian, Inc, Wallingford, CT
Accelrys Software Inc (2013) Discovery studio modeling environment, Release 3.5. Accelrys Software Inc, San Diego
Momany FA, Rone RJ (1992) Comp Chem 13:888
Trott O, Olson AJ (2010) J Comput Chem 31:45
Eberhardt J, Santos-Martins D, Tillack AF, Forli S (2021) J Chem Inf Model 61:3891
Acknowledgements
Thanks to İnönü University for all of the spectral analysis. The authors thank Esin Akı Yalcin and the research group for technical assistance. The numerical calculations reported in this paper were partially performed at the TUBITAK ULAKBIM High Performance and Grid Computing Center (TRUBA resources).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yılmaz, Ü., Demir, Y., Taşkın Tok, T. et al. Bisbenzimidazole salts and their in silico–in vitro inhibitory abilities on hCA I, hCA II, and AChE enzymes. Monatsh Chem 155, 653–662 (2024). https://doi.org/10.1007/s00706-024-03204-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00706-024-03204-5